Highlights from the 2015 Hatch-Waxman Series, Paragraph IV Disputes Conference, NY, NY
Master the litigation strategies that your company needs to successfully scale the legal intricacies of this next crag of the patent cliff.
It is estimated that the industry will experience patent losses approaching $150 billion within the next three years.* This will undoubtedly test the balance of power created by the Hatch-Waxman Act and lead to dramatic new litigation challenges for brand names and generics.
Come to this conference and meet with the leading legal minds in this area as you acquire the skills needed for the new era of extreme Hatch-Waxman litigation.
Now in its eighth iteration, American Conference Institute’s (ACI’s) Paragraph IV Disputes conference is the only event which helps both brand name and generic pharmaceutical companies make sense of changing industry dynamics precipitated by the patent cliff and other factors such as patent reform, regulatory shifts and recent and pending case law. This is the conference that not only sets the standards for Paragraph IV litigation, but also serves as the annual meeting place for the “who’s who” of pharmaceutical patent litigation.
With the help and input of ACI’s Hatch-Waxman Advisory Board, we have designed this conference as a true symposium. At this gathering, there will be in-depth discussions and practical take-aways that will prepare you for this new era of extreme Hatch-Waxman litigation. Critical sessions will address all facets of Paragraph IV litigation from pre-litigation concerns to the commencement of suit through final adjudication. Most importantly, our faculty will delve deeply into the re-shaping of these elements by an evolving legal, regulatory, and procedural schematic and the harsh economic realities of the patent cliff.
July 13, 2015